The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience. - Université Sorbonne Paris Nord Accéder directement au contenu
Article Dans Une Revue Blood Année : 2012

The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience.

Dates et versions

hal-00771184 , version 1 (08-01-2013)

Identifiants

Citer

Mathilde Lamarque, Sophie Raynaud, Raphael Itzykson, Sylvain Thepot, Bruno Quesnel, et al.. The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience.. Blood, 2012, 120 (25), pp.5084-5. ⟨10.1182/blood-2012-09-453555⟩. ⟨hal-00771184⟩
200 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More